
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health, Inc. has demonstrated a robust two-year revenue compound annual growth rate (CAGR) of 28% projected from 2023 to 2025, indicating strong financial momentum. The company's growth is supported by anticipated advancements in colorectal cancer, breast cancer, and other indications, as well as the development of new monitoring applications and products like Reveal Ultra. Additionally, the expansion of reimbursement coverage for molecular residual disease (MRD) tests is expected to further enhance the company's commercial performance, leading to revised long-term revenue growth and margin assumptions in their financial projections.
Bears say
Guardant Health's recent medium-term revenue guidance for its Shield product has been perceived as underwhelming, raising concerns about the company's growth potential. Additionally, the organization faces significant risks related to regulatory approvals, reimbursement processes, and potential delays in product launches, which may adversely affect its stock performance. Increased research and development expenses, necessary for leveraging its Smart Liquid Biopsy platform and advancing product innovation, are likely to further strain financial stability in the near term.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares